about
C-peptide as a Therapy for Kidney Disease: A Systematic Review and Meta-AnalysisProtein- and diabetes-induced glomerular hyperfiltration: role of glucagon, vasopressin, and ureaInhibition of soluble epoxide hydrolase is renoprotective in 5/6 nephrectomized Ren-2 transgenic hypertensive ratsAssociation of sickle cell trait with chronic kidney disease and albuminuria in African Americans.Characterization of renin-angiotensin system enzyme activities in cultured mouse podocytes.Common charge-shift mutation Glu65Lys in K+ channel β₁-Subunit KCNMB1: pleiotropic consequences for glomerular filtration rate and progressive renal diseaseObesity in kidney disease: A heavyweight opponent.Glomerular sclerosis is prevented during urinary tract obstruction due to podocyte protectionBone marrow-derived progenitor cells do not contribute to podocyte turnover in the puromycin aminoglycoside and renal ablation models in rats.A glimpse of matrix metalloproteinases in diabetic nephropathy.Erk in kidney diseases.Podocyte injury damages other podocytes.Obesity, metabolic syndrome and diabetic nephropathyUrsolic acid attenuates diabetic mesangial cell injury through the up-regulation of autophagy via miRNA-21/PTEN/Akt/mTOR suppressionPodocyte hypertrophy precedes apoptosis under experimental diabetic conditions.Intrauterine growth restriction is associated with persistent aortic wall thickening and glomerular proteinuria during infancy.Vasculature and kidney complications in sickle cell disease.Morphine promotes renal pathology in sickle mice.Low Birth Weight due to Intrauterine Growth Restriction and/or Preterm Birth: Effects on Nephron Number and Long-Term Renal Health.Targeting glucagon receptor signalling in treating metabolic syndrome and renal injury in Type 2 diabetes: theory versus promiseActivation of the Renal PI3K/Akt/mTOR Signaling Pathway in a DOCA-Salt Model of Hypertension.Obesity and diabetic kidney disease.Glucagon receptor-mediated extracellular signal-regulated kinase 1/2 phosphorylation in rat mesangial cells: role of protein kinase A and phospholipase C.Distinguishing diabetic nephropathy from other causes of glomerulosclerosis: an update.Pathophysiology of focal segmental glomerulosclerosis.Fetal hypoxia results in programming of aberrant angiotensin ii receptor expression patterns and kidney developmentPhlorizin prevents glomerular hyperfiltration but not hypertrophy in diabetic rats.Six Months of Hydroxyurea Reduces Albuminuria in Patients with Sickle Cell Disease.Current insights and new perspectives on the roles of hyperglucagonemia in non-insulin-dependent type 2 diabetes.Morphine stimulates platelet-derived growth factor receptor-β signalling in mesangial cells in vitro and transgenic sickle mouse kidney in vivo.Long-term hyperglucagonaemia induces early metabolic and renal phenotypes of Type 2 diabetes in mice.Impact of gestational age and birth weight on amikacin clearance on day 1 of life.Mammalian target of rapamycin and the kidney. II. Pathophysiology and therapeutic implications.Sickle cell disease: renal manifestations and mechanismsUpdate on blood pressure control and renal outcomes in diabetes mellitus.Does significant renal ablation truly and invariably lead to hyperfiltration and progressive chronic kidney disease?Hyperfiltration-associated biomechanical forces in glomerular injury and response: Potential role for eicosanoids.Mammalian target of rapamycin (mTOR) as a potential therapeutic target in various diseases.Sickle Cell Trait and the Risk of ESRD in Blacks.cAMP activates TRPC6 channels via the phosphatidylinositol 3-kinase (PI3K)-protein kinase B (PKB)-mitogen-activated protein kinase kinase (MEK)-ERK1/2 signaling pathway.
P2860
Q27306601-B92617C6-057D-464B-9F22-3B7B0BDADC30Q28085593-DEAD02C7-32EA-4A53-B4C0-D2FC3FD6AA75Q28659091-3EF4A602-DAAD-42CB-9B2C-7006B9916C11Q30301317-40C630D5-FBCD-4638-8D4B-6272C0592D8FQ33281856-D853594A-7146-40F1-A33E-B140CF6D7E40Q34287908-9DFC6F5A-980B-4CA2-88C3-F95EC60B41FFQ34367664-3D2A9CF2-A91A-4CA6-85AB-91ED4F9477CDQ34719120-081062F4-47F5-4D33-A1A3-782BE2B1CFAEQ34756227-5C8A6D26-90B2-44F6-8117-8147E3A3E8D0Q34796034-F2B4C471-DE8B-44E2-BCF8-56E9C045AE15Q35101922-032DE29E-CEEB-4C71-A59A-1849657D8CE4Q35108875-3307608A-68C8-4C4C-AF3E-F1C55B31D170Q35224446-07F2483F-2295-4985-A71A-50E498280788Q35562829-C84FB4AC-851C-4296-93AD-2F20F92C4A96Q35624799-A1BC32A4-A5D1-4961-A1D3-7C981DD0A8F6Q35669336-E1C11E7F-DB98-40A3-B8AD-C3DC5969D3CEQ35917528-9FD7592B-BE44-4C8A-B6A2-710A678DAA43Q36144403-A0B0527C-FD85-43AA-81DE-3566AE6783DEQ36210529-0E886283-D4CA-4E3D-9062-963D816510FEQ36514704-35B988C5-7528-4049-A7C6-33C7BCF2733DQ36514846-36C8F921-169D-4880-ADD1-F8BB720CC65EQ36515043-598D0967-B33D-435E-9F0B-F9533F34A04EQ36632374-F4303495-8CD9-498C-8BBB-67932C6B4601Q36703450-E4A2962A-B974-469E-A6F5-1ED9ECAD5041Q36704678-8EEA1093-FA25-4B69-9D3D-067BE7A3D5A2Q36713409-C47434D9-D007-4690-A5CB-F16018A115E9Q36848932-A1AF0DE2-84B8-41AF-ACF0-F040F02CD0F5Q36944638-BE0CB371-5769-489E-9D99-1A12CC610981Q37260041-1B97C3A2-FD24-49DC-B967-F6EABFE553F7Q37308492-461083C9-D372-4403-A48A-F609126E3636Q37412849-5C4C669F-5CFC-4DE4-9DBA-0B2A8EA735CDQ37415700-2F33ECE7-A652-4776-A466-0E3D5CAD7EDBQ38002007-8E1DCEE4-C9A0-41B6-837D-A949169E7955Q38350669-4D95243A-1A72-47D4-998C-EDECBFEC80C4Q38492248-B45625FD-0864-45A4-A342-2FE175938C99Q38979973-EFF5243A-D12E-4E56-8B53-99F2FD3B9724Q39096936-5863D3DB-B9BF-45FD-AFEA-158566417D5CQ39247355-0FFAEA06-995A-4D27-8D70-3A9F06B3876BQ40298866-AD1C0276-15D9-4B90-AAEC-F6674632D124Q41809171-03B55107-0F06-4220-8780-B045EDFD7C4C
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մարտին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Hyperfiltration and glomerulosclerosis.
@ast
Hyperfiltration and glomerulosclerosis.
@en
type
label
Hyperfiltration and glomerulosclerosis.
@ast
Hyperfiltration and glomerulosclerosis.
@en
prefLabel
Hyperfiltration and glomerulosclerosis.
@ast
Hyperfiltration and glomerulosclerosis.
@en
P356
P1476
Hyperfiltration and glomerulosclerosis.
@en
P2093
Thomas H Hostetter
P304
P356
10.1053/ANEP.2003.50017
P577
2003-03-01T00:00:00Z